世界の良性前立腺肥大症治療薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Benign Prostate Hyperplasia Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12084
• 出版社/出版日：GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、108ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料では、良性前立腺肥大症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。良性前立腺肥大症治療薬の種類別市場規模（アルファ遮断薬、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・良性前立腺肥大症治療薬の市場概要
・企業情報（企業概要、製品概要、販売量、価格、売上）：Sanofi、Coloplast、Pfizer、Merck、GlaxoSmithKline、Eli Lilly and Company、Abbott Laboratories、Teva Pharmaceuticals、Allergan、Boehringer Ingelheim
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年：アルファ遮断薬、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他
・用途別分析2016年-2026年：病院、クリニック、その他
・良性前立腺肥大症治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ
・良性前立腺肥大症治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア
・良性前立腺肥大症治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア
・良性前立腺肥大症治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン
・良性前立腺肥大症治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Benign Prostate Hyperplasia Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Benign Prostate Hyperplasia Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Benign Prostate Hyperplasia Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Benign Prostate Hyperplasia Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others

Market segment by Application, can be divided into
Hospital
Clinic
Other

Market segment by players, this report covers
Sanofi
Coloplast
Pfizer
Merck
GlaxoSmithKline
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan
Boehringer Ingelheim

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Benign Prostate Hyperplasia Drugs
1.2 Classification of Benign Prostate Hyperplasia Drugs by Type
1.2.1 Overview: Global Benign Prostate Hyperplasia Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type in 2020
1.2.3 Alpha Blocker
1.2.4 5-Alpha Reductase Inhibitor
1.2.5 Phosphodiesterase-5 Inhibitor
1.2.6 Others
1.3 Global Benign Prostate Hyperplasia Drugs Market by Application
1.3.1 Overview: Global Benign Prostate Hyperplasia Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Benign Prostate Hyperplasia Drugs Market Size & Forecast
1.5 Global Benign Prostate Hyperplasia Drugs Market Size and Forecast by Region
1.5.1 Global Benign Prostate Hyperplasia Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Benign Prostate Hyperplasia Drugs Market Size by Region, (2016-2021)
1.5.3 North America Benign Prostate Hyperplasia Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Benign Prostate Hyperplasia Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Benign Prostate Hyperplasia Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Benign Prostate Hyperplasia Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Benign Prostate Hyperplasia Drugs Market Drivers
1.6.2 Benign Prostate Hyperplasia Drugs Market Restraints
1.6.3 Benign Prostate Hyperplasia Drugs Trends Analysis
2 Company Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Benign Prostate Hyperplasia Drugs Product and Solutions
2.1.4 Sanofi Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Coloplast
2.2.1 Coloplast Details
2.2.2 Coloplast Major Business
2.2.3 Coloplast Benign Prostate Hyperplasia Drugs Product and Solutions
2.2.4 Coloplast Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Coloplast Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Benign Prostate Hyperplasia Drugs Product and Solutions
2.3.4 Pfizer Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Benign Prostate Hyperplasia Drugs Product and Solutions
2.4.4 Merck Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Merck Recent Developments and Future Plans
2.5 GlaxoSmithKline
2.5.1 GlaxoSmithKline Details
2.5.2 GlaxoSmithKline Major Business
2.5.3 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Product and Solutions
2.5.4 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 GlaxoSmithKline Recent Developments and Future Plans
2.6 Eli Lilly and Company
2.6.1 Eli Lilly and Company Details
2.6.2 Eli Lilly and Company Major Business
2.6.3 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Product and Solutions
2.6.4 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Eli Lilly and Company Recent Developments and Future Plans
2.7 Abbott Laboratories
2.7.1 Abbott Laboratories Details
2.7.2 Abbott Laboratories Major Business
2.7.3 Abbott Laboratories Benign Prostate Hyperplasia Drugs Product and Solutions
2.7.4 Abbott Laboratories Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Abbott Laboratories Recent Developments and Future Plans
2.8 Teva Pharmaceuticals
2.8.1 Teva Pharmaceuticals Details
2.8.2 Teva Pharmaceuticals Major Business
2.8.3 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Product and Solutions
2.8.4 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Teva Pharmaceuticals Recent Developments and Future Plans
2.9 Allergan
2.9.1 Allergan Details
2.9.2 Allergan Major Business
2.9.3 Allergan Benign Prostate Hyperplasia Drugs Product and Solutions
2.9.4 Allergan Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Allergan Recent Developments and Future Plans
2.10 Boehringer Ingelheim
2.10.1 Boehringer Ingelheim Details
2.10.2 Boehringer Ingelheim Major Business
2.10.3 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Product and Solutions
2.10.4 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Boehringer Ingelheim Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Benign Prostate Hyperplasia Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Benign Prostate Hyperplasia Drugs Players Market Share
3.2.2 Top 10 Benign Prostate Hyperplasia Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Benign Prostate Hyperplasia Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Benign Prostate Hyperplasia Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Benign Prostate Hyperplasia Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Application (2016-2021)
5.2 Benign Prostate Hyperplasia Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2026)
6.2 North America Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2026)
6.3 North America Benign Prostate Hyperplasia Drugs Market Size by Country
6.3.1 North America Benign Prostate Hyperplasia Drugs Revenue by Country (2016-2026)
6.3.2 United States Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2026)
7.2 Europe Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2026)
7.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Country
7.3.1 Europe Benign Prostate Hyperplasia Drugs Revenue by Country (2016-2026)
7.3.2 Germany Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
7.3.3 France Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Region
8.3.1 Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Region (2016-2026)
8.3.2 China Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
8.3.5 India Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2026)
9.2 South America Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2026)
9.3 South America Benign Prostate Hyperplasia Drugs Market Size by Country
9.3.1 South America Benign Prostate Hyperplasia Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Country
10.3.1 Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Benign Prostate Hyperplasia Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Benign Prostate Hyperplasia Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Benign Prostate Hyperplasia Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Benign Prostate Hyperplasia Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Benign Prostate Hyperplasia Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Region (2021-2026)
Table 6. Sanofi Corporate Information, Head Office, and Major Competitors
Table 7. Sanofi Major Business
Table 8. Sanofi Benign Prostate Hyperplasia Drugs Product and Solutions
Table 9. Sanofi Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Coloplast Corporate Information, Head Office, and Major Competitors
Table 11. Coloplast Major Business
Table 12. Coloplast Benign Prostate Hyperplasia Drugs Product and Solutions
Table 13. Coloplast Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Pfizer Corporate Information, Head Office, and Major Competitors
Table 15. Pfizer Major Business
Table 16. Pfizer Benign Prostate Hyperplasia Drugs Product and Solutions
Table 17. Pfizer Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Merck Corporate Information, Head Office, and Major Competitors
Table 19. Merck Major Business
Table 20. Merck Benign Prostate Hyperplasia Drugs Product and Solutions
Table 21. Merck Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 23. GlaxoSmithKline Major Business
Table 24. GlaxoSmithKline Benign Prostate Hyperplasia Drugs Product and Solutions
Table 25. GlaxoSmithKline Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 27. Eli Lilly and Company Major Business
Table 28. Eli Lilly and Company Benign Prostate Hyperplasia Drugs Product and Solutions
Table 29. Eli Lilly and Company Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 31. Abbott Laboratories Major Business
Table 32. Abbott Laboratories Benign Prostate Hyperplasia Drugs Product and Solutions
Table 33. Abbott Laboratories Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Teva Pharmaceuticals Major Business
Table 36. Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Product and Solutions
Table 37. Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Allergan Corporate Information, Head Office, and Major Competitors
Table 39. Allergan Major Business
Table 40. Allergan Benign Prostate Hyperplasia Drugs Product and Solutions
Table 41. Allergan Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 43. Boehringer Ingelheim Major Business
Table 44. Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Product and Solutions
Table 45. Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Benign Prostate Hyperplasia Drugs Revenue (USD Million) by Players (2019-2021)
Table 47. Global Benign Prostate Hyperplasia Drugs Revenue Share by Players (2019-2021)
Table 48. Breakdown of Benign Prostate Hyperplasia Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Benign Prostate Hyperplasia Drugs Players Head Office, Products and Services Provided
Table 50. Benign Prostate Hyperplasia Drugs Mergers & Acquisitions in the Past Five Years
Table 51. Benign Prostate Hyperplasia Drugs New Entrants and Expansion Plans
Table 52. Global Benign Prostate Hyperplasia Drugs Revenue (USD Million) by Type (2016-2021)
Table 53. Global Benign Prostate Hyperplasia Drugs Revenue Share by Type (2016-2021)
Table 54. Global Benign Prostate Hyperplasia Drugs Revenue Forecast by Type (2021-2026)
Table 55. Global Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2021)
Table 56. Global Benign Prostate Hyperplasia Drugs Revenue Forecast by Application (2021-2026)
Table 57. North America Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Benign Prostate Hyperplasia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Benign Prostate Hyperplasia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Benign Prostate Hyperplasia Drugs Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Benign Prostate Hyperplasia Drugs Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Benign Prostate Hyperplasia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Benign Prostate Hyperplasia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Benign Prostate Hyperplasia Drugs Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Benign Prostate Hyperplasia Drugs Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Benign Prostate Hyperplasia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Benign Prostate Hyperplasia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Benign Prostate Hyperplasia Drugs Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Benign Prostate Hyperplasia Drugs Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Benign Prostate Hyperplasia Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Benign Prostate Hyperplasia Drugs Picture
Figure 2. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type in 2020
Figure 3. Alpha Blocker
Figure 4. 5-Alpha Reductase Inhibitor
Figure 5. Phosphodiesterase-5 Inhibitor
Figure 6. Others
Figure 7. Benign Prostate Hyperplasia Drugs Revenue Market Share by Application in 2020
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Other Picture
Figure 11. Global Benign Prostate Hyperplasia Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Benign Prostate Hyperplasia Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Region (2016-2026)
Figure 14. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Region in 2020
Figure 15. North America Benign Prostate Hyperplasia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Benign Prostate Hyperplasia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Benign Prostate Hyperplasia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Benign Prostate Hyperplasia Drugs Market Drivers
Figure 21. Benign Prostate Hyperplasia Drugs Market Restraints
Figure 22. Benign Prostate Hyperplasia Drugs Market Trends
Figure 23. Sanofi Recent Developments and Future Plans
Figure 24. Coloplast Recent Developments and Future Plans
Figure 25. Pfizer Recent Developments and Future Plans
Figure 26. Merck Recent Developments and Future Plans
Figure 27. GlaxoSmithKline Recent Developments and Future Plans
Figure 28. Eli Lilly and Company Recent Developments and Future Plans
Figure 29. Abbott Laboratories Recent Developments and Future Plans
Figure 30. Teva Pharmaceuticals Recent Developments and Future Plans
Figure 31. Allergan Recent Developments and Future Plans
Figure 32. Boehringer Ingelheim Recent Developments and Future Plans
Figure 33. Global Benign Prostate Hyperplasia Drugs Revenue Share by Players in 2020
Figure 34. Benign Prostate Hyperplasia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Benign Prostate Hyperplasia Drugs Revenue Market Share in 2020
Figure 36. Global Top 10 Players Benign Prostate Hyperplasia Drugs Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Benign Prostate Hyperplasia Drugs Revenue Share by Type in 2020
Figure 39. Global Benign Prostate Hyperplasia Drugs Market Share Forecast by Type (2021-2026)
Figure 40. Global Benign Prostate Hyperplasia Drugs Revenue Share by Application in 2020
Figure 41. Global Benign Prostate Hyperplasia Drugs Market Share Forecast by Application (2021-2026)
Figure 42. North America Benign Prostate Hyperplasia Drugs Sales Market Share by Type (2016-2026)
Figure 43. North America Benign Prostate Hyperplasia Drugs Sales Market Share by Application (2016-2026)
Figure 44. North America Benign Prostate Hyperplasia Drugs Revenue Market Share by Country (2016-2026)
Figure 45. United States Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Benign Prostate Hyperplasia Drugs Sales Market Share by Type (2016-2026)
Figure 49. Europe Benign Prostate Hyperplasia Drugs Sales Market Share by Application (2016-2026)
Figure 50. Europe Benign Prostate Hyperplasia Drugs Revenue Market Share by Country (2016-2026)
Figure 51. Germany Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Benign Prostate Hyperplasia Drugs Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Benign Prostate Hyperplasia Drugs Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue Market Share by Region (2016-2026)
Figure 59. China Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Benign Prostate Hyperplasia Drugs Sales Market Share by Type (2016-2026)
Figure 66. South America Benign Prostate Hyperplasia Drugs Sales Market Share by Application (2016-2026)
Figure 67. South America Benign Prostate Hyperplasia Drugs Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Benign Prostate Hyperplasia Drugs Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Benign Prostate Hyperplasia Drugs Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source

Global Benign Prostate Hyperplasia Drugs Market 2019 by Company, Regions, Type and Application, Forecast to 2024
C-GIR20G2539 2019年12月30日 100Pages
「良性前立腺過形成薬の世界市場2019年」は、グローバルにおける良性前立腺過形成薬市場を展望するレポートです。良性前立腺過形成薬のグローバル市場概観、企業動向、企業別シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメ...

世界の良性前立腺肥大症治療市場 2021：企業別、地域別、種類・用途別

Global Benign Prostatic Hyperplasia Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A13990 2021年7月 123Pages
当調査資料では、良性前立腺肥大症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。良性前立腺肥大症治療の種類別市場規模（医薬品、低侵襲手術、レーザー治療、その他）、用途別市場規模（病院、外来手術センター、専門クリニック、その他）、地域別市場規模（北米...

世界の良性前立腺過形成（BPH）治療市場予測（～2024年）

Global Benign Prostatic Hyperplasia (BPH) Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR09D3807 2019年9月18日 121Pages
本調査レポートは、良性前立腺過形成（BPH）治療の世界市場について調べ、まとめました。種類別セグメントは、薬、デバイス等、用途別セグメントは、病院、診療所、その他等に区分しました。良性前立腺過形成（BPH）治療の世界市場概観、企業動向、企業別良性前立腺過形成（BPH）治療シェア、市場規模推移、市場規...

世界の前立腺がん市場 2021：企業別、地域別、種類・用途別

Global Prostate Cancer Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12620 2021年7月 80Pages
当調査資料では、前立腺がんのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。前立腺がんの種類別市場規模（化学療法、ホルモン療法、標的療法、免疫療法）、用途別市場規模（55歳以下、55〜75歳、75歳以上）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジ...

世界の前立腺ステント市場 2021：企業別、地域別、種類・用途別

Global Prostate Stent Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-107A13540 2021年7月 94Pages
当調査資料では、前立腺ステントのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。前立腺ステントの種類別市場規模（金属製前立腺ステント、プラスチック製前立腺ステント、その他）、用途別市場規模（病院、外来手術センター、専門クリニック、その他）、地域別市場規模...

世界の前立腺特異抗原市場 2021：企業別、地域別、種類・用途別

Global Prostate Specific Antigen Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-107A14690 2021年7月 86Pages
当調査資料では、前立腺特異抗原のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。前立腺特異抗原の種類別市場規模（G-115、INO-5150、ADXS-PSA、AEZS-120、その他）、用途別市場規模（前立腺がん、転移性ホルモン不応性前立腺がん、その他...

世界のがんホルモン療法剤市場 2021：企業別、地域別、種類・用途別

Global Cancer Hormone Therapy Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12131 2021年7月 108Pages
当調査資料では、がんホルモン療法剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。がんホルモン療法剤の種類別市場規模（タモキシフェン、アロマターゼ阻害剤、抗アンドロゲン、アンドロゲン合成阻害剤、その他）、用途別市場規模（乳がん、前立腺がん）、地域別市場...

世界のテデュグルチド薬市場 2021：企業別、地域別、種類・用途別

Global Teduglutide Drugs Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-107A14768 2021年7月 101Pages
当調査資料では、テデュグルチド薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。テデュグルチド薬の種類別市場規模（ガテックス、レベスティブ）、用途別市場規模（病院、薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジ...

世界の前立腺特異抗原（PSA）検査市場 2021：企業別、地域別、種類・用途別

Global Prostate-specific Antigen (PSA) Testing Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12623 2021年7月 121Pages
当調査資料では、前立腺特異抗原（PSA）検査のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。前立腺特異抗原（PSA）検査の種類別市場規模（CLIA法、ELISA法）、用途別市場規模（スクリーニング、治療後モニタリング、その他）、地域別市場規模（北米、ア...

世界の間質性膀胱炎治療薬市場 2021：企業別、地域別、種類・用途別

Global Interstitial Cystitis Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12394 2021年7月 103Pages
当調査資料では、間質性膀胱炎治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。間質性膀胱炎治療薬の種類別市場規模（経口療法、膀胱内療法）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国...

良性前立腺過形成薬の世界市場 2019年版：種類別（アルファブロッカー、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）、用途別（病院、クリニック、その他） Description Scope of the Report: The global Benign Prostate Hyperplasia Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, …
世界の良性前立腺過形成（BPH）治療市場予測（～2024年） Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infec…
世界の良性前立腺肥大症治療市場 2021：企業別、地域別、種類・用途別 The Benign Prostatic Hyperplasia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…
世界の前立腺がん市場 2021：企業別、地域別、種類・用途別 The Prostate Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, re…
世界の前立腺ステント市場 2021：企業別、地域別、種類・用途別 The Prostate Stent market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, rec…